China To Further Squeeze Distribution Margins And Limit Drug Markups In Hospitals
This article was originally published in PharmAsia News
The National People’s Congress and Chinese Peoples’ Political Consultative Conference will bring in March a variety of new policies and regulations that will impact the industry.
You may also be interested in...
China Signals Need For Private Investment To Support Its Healthcare Reforms; Private Insurance Options Likely To Widen
SHANGHAI - China recently lifted a ban on foreign investment in medical institutes to support its $124 billion healthcare reforms and the establishment of wholly foreign-owned hospitals and clinics. The move by the Chinese government is being read as a signal that China may open more of the country's healthcare industry to foreign investment
SHANGHAI - The National Development and Reform Commission, China's powerful economic regulatory body, is collecting feedback from industry for a new drug pricing guideline, which details new rules for setting drug prices in China's changing healthcare system
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.